George Frangeskides, Chairman at ALBA, explains why the Pilbara Lithium option ‘was too good to miss’. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Very sensible, PB. IMO, it is probably mainly traders positioning for an update, rather than a leak.
In fact, IMO if it was a leak, the SP would already have spiked far, far higher - or lower - than this, so personally, I would discount that notion.
Not long to find out anyway. A few weeks at most now I would imagine? GLA.
Nice to see an uptick - wonder if someone has knowledge of the data? Hopefully it's released very soon and demonstrates the promise that has been indicated by the company.
Still steadfastly refuse to get excited by any movements at this level though - deep underwater...
Agreed.
Hopefully busicat. That would make a nice change :)
To the poster mentioning STX: I am a fairly LTH in that one. While I have bottom-drawed my shares, I would not dream of recommending it here or elsewhere. The less said about the previous BOD the better (which may feel familiar to LTH of RENE also!), but the current CEO is still a long way off delivering for shareholders anywhere near enough to justify his current remuneration either. I suppose I should add an 'IMO' to that last statement. By all means, take a look over there and draw your own conclusions from all the RNS material, financial reports etc. But yes, it does have a product now in the market and growing.
Anyway, back on topic. Nice to see the SP action of late in RENE. In Iain, we trust :) GLA.
I think Rene is primed and ready for it's next move up. The data will be available now and hopefully the company will be discussing with partners with a view to signing deals. Hoping for an Rns to update us on the findings of the data.
Fair enough toptiger but when I posted about Dest on the 24th July the share price was 31p it went on to hit 52p over the next few days. So you could have made some decent money like me.
These pharma companys ARE MONEY EATING ONLY A FEW MAKE the grade . Better ways to invest imo brightest one now is stx .shield t
Who the hell would want another pharma after this experience ? they are without doubt the WORST investments possible, you want years and years and years for nendless trials, almost all dont work, and you keep getting placings.
def not interested
LWHL, looks like you were right not to wait for lower 8's this time : )
I will apologise upfront for this post. I know many on here are suffering a big loss on their investment, as I am also. The aim of this post is to bring to your attention a company that I think will do very well and urge you to research it. The company is Destiny Pharma (Dest) and I have a substantial holding in it. I will give a few brief points about it.
1. It has 2 phase 3 ready drugs - one is licensed already and in discussions with partners for the other.
2. NIAID of USA is paying for pre clinical trials for one of the drugs XF-73 with a view for using it in wounds for the USA army.
3. Excellent results for Sporcov for Covid and influenza.
4. New CEO appointed - Was at GW Pharma that got taken over for $7.2B, currently at Jazz pharma $8.3B. Also worked for GSK. Why would he join a company that has a mcap of £29M.
5. I believe XF-73 will be standard of care for almost every operation in the future, try putting a price on that.
I won't bore you with anymore, but feel free to come to the Dest chat and ask any questions you may have. Once again apologies for this off topic post.
That sounds plausible, although I do not have my ear to the ground, so no strong opinion one way or the other on that.
If Iain and the team can deliver (as I think they will), it will be so satisfying, because it will, IMO, represent a terrific turnaround story.
And it will be gratifying to have been a very small part of that journey.
Obviously the potential financial gain will be nice too, if it comes to pass :)
Just going to put here what I am hearing, take it with a pinch of salt. The in vivo data is looking very good ( this was more or less confirmed in the recent presentation) and we are likely to sign 2 types of deals with interested parties. Now the interesting part is that we have partnerships with pharma companies that are likely to sign deals if the data is good enough, however a number of companies that do not have partnerships with us have also approached the company and want to see the data with a view to signing a deal. The deals will be either a technology platform partnership or we will license the platform.
I picked up another 10K today. Was going to wait for low 8's, which will probably come, as I always jump the gun, but that is me fully loaded for now. GLA.
Good spot, thanks for that Narrative. Amazing that they have raised such a large amount of money for a company that has only done a few animal studies. The similarities to RENE are striking, though it is not clear where they will go with this first. Macular degeneration is mentioned on their website, but not retinitis pigmentosa specifically.
$70M Series 'A' funding for eye therapies using stemcell/ iPSC and possibly exosome tech? Could make a nice partner, if they're not already! That said, they could be competition...
https://www.tenpointtherapeutics.com/press-releases/tenpoint-therapeutics-launches-with-70-million-series-a-financing-to-reverse-vision-loss-through-engineered-cell-based-therapeutics-and-in-vivo-reprogramming/
One of the founders, Peter Coffey, I think has done work with Reneuron in the past at UCL. DYOR.
True. The price will probably drift back to sub 9p, maybe even back to 8p, while we wait for news.
Will take a view on whether I want to add a few more at that point. If that point comes, of course.
Good weekend all.
That was the main reason I bought more at around 7p and averaged down. I do think that will be the last director buy for now as they will be in a closed period soon if not already.
When you also consider that there are less than 58 million shares in issue, and a fairly small free float too, IMO any good news is unlikely to lead to a gradual rise in the SP either.
Absolutely high risk unless/until the BOD deliver, in case I am in danger of straying into ramping territory, but these are some of the things to be aware of, IMO.
I make it 14 separate share purchases by directors within the last 12 months, with approximately 1.2m shares bought.
Well, I am pleased to see another inside buy here.
Whether we shareholders win or lose at the end of the day, I for one feel far more respect for them than the boat loads of AIM lifestyle directors who refuse to put their hand in their pocket.
I retain full faith in the management and continue to back them to deliver! GLA.
It is obvious the data is looking very good, was hinted at in the presentation. A number of parties are waiting to see the data before committing to deals. As per the presentation Iain said the in vivo data will be available any day now. At this price it has to be a strong buy.
It's going to look pretty obvious in hindsight if something positive comes out and this company turns around in the near to medium term. Lots of director buys over a sustained period, coupled with lots of positive and bullish rhetoric in the various presentations.
Will it happen? I don't know, hopefully.
Hope springs eternal!
Sporadic interest again. Perhaps someone/something accumulating carefully?
About 90% plus of biotech start-ups fail during clinical trials so there’s little that’s unusual about Reneuron. But yes poor leadership and poor cash management can and possibly has contributed to failure but equally good science can and does fail. Of course many of us, me included, hoped we and Reneuron would be on the right side of that curve where rewards would be eye-watering, however when I joined the ride too many years ago to remember, I knew that probability suggested I’d end up 100% down! Nonetheless it’s good to hear that some think even now there’s a British knight in shining armour out there. If one should happen to ride in, the question I suppose is, by how much will we then still be down? But fingers crossed as they say.